Venous thromboembolism · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Apixaban monotherapy Variant #05 | — | R 2 232 | 180d | — | — | — | — | — |
Enoxaparin monotherapy Variant #01 | — | R 1 709 | 14d | — | — | — | — | — |
Rivaroxaban monotherapy Variant #05 | — | R 1 032 | 90d | — | — | — | — | — |
Aspirin monotherapy Variant #01 | — | R 26 | 28d | — | — | — | — | — |
Observation Partial | — | — | — | ~10.3 mo | ~37.1 mo | — | — | 65 |
Betrixaban monotherapy Variant #01 Partial | — | — | 42d | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
7 of 7 regimens shown